DSIP drug products
This guide does not identify a current FDA-approved DSIP drug product.
Current sourceDSIP
Sleep-peptide research signals and the limits of claims about insomnia, stress, and recovery
Delta sleep-inducing peptide, or DSIP, appears in older sleep and stress research and in modern online peptide marketing. The evidence base is fragmented, and claims about treating insomnia, anxiety, pain, or recovery should not be treated as established clinical guidance.
Editorial status
This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: .
It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.
Product and regulatory distinctions
A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.
Compounded DSIP
Compounded products are not FDA-approved for safety, effectiveness, or quality before marketing.
Current sourceSleep and mental-health use
Symptoms such as insomnia, anxiety, pain, or withdrawal require clinical evaluation rather than reliance on peptide marketing.
Current sourceClaim-by-claim evidence map
Each finding is tied to the population and product actually studied. Trial results are not personal predictions.
Small controlled human studies reported mixed sleep findings, without establishing DSIP as an insomnia treatment.
- Population
- Six healthy volunteers in a double-blind crossover study and 16 people with chronic insomnia in a double-blind matched-pairs study.
- Finding
- The six-person study reported acute and delayed sleep changes; the 16-person insomnia study found weak objective effects, no subjective sleep-quality change, and concluded that major short-term therapeutic benefit was unlikely.
- Limits
- The accessible records do not establish randomized allocation. Both studies were small, used intravenous DSIP, and were published in 1981 and 1992; they do not establish effectiveness, contemporary dosing, or safety for marketed injectable products.
Sleep architecture claims require objective measurement and clinical context.
- Population
- People considering DSIP for sleep quality.
- Finding
- Subjective sleep improvement and objective sleep-stage changes are different endpoints.
- Limits
- Self-tracking cannot diagnose sleep apnea, mood disorders, pain syndromes, or medication effects.
A vial label does not establish identity or sterility.
- Population
- Users of online injectable DSIP products.
- Finding
- Quality attributes are product-specific and cannot be inferred from molecule name.
- Limits
- This page cannot verify any seller or product.
What this evidence does not answer
- No modern, adequately powered evidence base establishes DSIP for routine insomnia treatment.
- Long-term safety for repeated injectable use is not established.
- Interactions with sedatives, psychiatric medicines, alcohol, or sleep disorders require clinical review.
Useful information to organize between visits
- Sleep timing and awakenings
- Caffeine, alcohol, sedatives, and other medicines
- Product source and dates of any exposure
- Daytime symptoms and safety issues such as driving impairment
Questions to bring to a clinician or pharmacist
- 1.Should I be evaluated for sleep apnea or another treatable cause?
- 2.Could my medicines or alcohol use explain the sleep issue?
- 3.What evidence-supported sleep treatments fit my case?
Primary sources
- Acute and delayed effects of DSIP on human sleep behaviorInternational Journal of Clinical Pharmacology, Therapy, and Toxicology · Published 1981-08 · Accessed July 12, 2026
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind studyNeuropsychobiology · Published 1992 · Accessed July 12, 2026
- Sleep DisordersNational Heart, Lung, and Blood Institute · Published Current health information · Accessed July 12, 2026
- Drugs@FDA: FDA-Approved DrugsU.S. Food and Drug Administration · Published Current database · Accessed July 12, 2026
- Compounded Drugs: Questions and AnswersU.S. Food and Drug Administration · Published Current guidance · Accessed July 12, 2026
Turn scattered notes into a useful treatment history
Dosi organizes timing, locations, symptoms, reminders, and questions for your next appointment. It does not prescribe or replace your care team.
Start tracking free